SCHEMBL10072119

SCHEMBL10072119

COc1ccc(-c2cc(N3CCC[C@H]3CO)nc3c(-c4ccc(Cl)cc4)c(C)nn23)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
MAPK1 P28482 1/20 0.48
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.42
CRHR1 P34998 2/20 0.41
KCNH2 Q12809 1/20 0.41
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
CYP1A2 P05177 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
FPR2 P25090 1/20 0.39
SCN9A Q15858 1/20 0.39
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020899 1.00 MAPT (0.48) MAPTMAPK1TP53THRBCRHR1
SCHEMBL15020612 0.94 TP53 (0.50) MAPTTP53THRBCRHR1KMT2A
SCHEMBL15020744 0.93 MAPT (0.50) MAPTMAPK1THRBCRHR1KMT2A
SCHEMBL15021012 0.92 MAPT (0.59) MAPTMAPK1TP53CRHR1KMT2A
SCHEMBL257541 0.92 MAPT (0.59) MAPTMAPK1TP53CRHR1KMT2A
SCHEMBL15020675 0.92 MAPT (0.48) MAPTMAPK1TP53THRBCRHR1
SCHEMBL257407 0.92 MAPT (0.48) MAPTMAPK1TP53THRBCRHR1
SCHEMBL257379 0.91 MAPT (0.48) MAPTMAPK1CRHR1KMT2ACYP1A2
SCHEMBL15020684 0.91 MAPT (0.48) MAPTMAPK1CRHR1KMT2ACYP1A2
SCHEMBL15021371 0.91 TP53 (0.48) MAPTTP53CRHR1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885MAPK1 519/4885TP53 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.